Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Shionogi USA

IDWeek 2025: Shionogi Presents Real-World and Surveillance Data Reinforcing Role of Cefiderocol Across Range of Patient Populations and Difficult-to-Treat Infections
From Shionogi USA
Via Business Wire
Shionogi to Present New Data from Anti-Infective Portfolio at IDWeek
From Shionogi USA
Via Business Wire
FDA Accepts Shionogi’s Ensitrelvir NDA as the First Oral Therapy for the Prevention of COVID-19 Following Exposure
From Shionogi USA
Via Business Wire
Late-Breaking at CROI 2025: SCORPIO-PEP Phase 3 Trial: Ensitrelvir is the First and Only COVID-19 Oral Antiviral to Demonstrate Prevention of COVID-19 as Post Exposure Prophylaxis
From Shionogi USA
Via Business Wire
Shionogi and Jordan’s Guardian Angels Announce First-Ever Human Drug Study for Jordan’s Syndrome, an Ultra-Rare Genetic Neurodevelopmental Disorder
From Shionogi USA
Via Business Wire
Shionogi Receives Award Through BARDA's Rapid Response Partnership Vehicle to Advance Long-Acting Formulation of S-892216, an Antiviral for COVID-19 Pre-Exposure Prophylaxis in At-Risk Populations
From Shionogi USA
Via Business Wire
IDWeek 2024: Shionogi Presents Largest Global Real-World Evidence Study of Cefiderocol Demonstrating Strong Clinical Response Rates Across Seriously Ill Patients
From Shionogi USA
Via Business Wire
Shionogi Continues Global Commitment to Advances in Infectious Disease with Key Data Presentations from Its Expanding Product Portfolio at IDWeek 2024
From Shionogi USA
Via Business Wire
Shionogi Provides Updates on Zatolmilast, an Investigational Drug for Fragile X Syndrome, Including Recent Changes to Study Protocol to Increase Access for Participants and Families
From Shionogi USA
Via Business Wire
Shionogi Expands Global Infectious Disease and Antimicrobial Research Operations to U.S. to Address Current and Emerging Health Threats
From Shionogi USA
Via Business Wire
Shionogi & Co., Ltd. and Maze Therapeutics, Inc. Announce Exclusive Worldwide License Agreement for MZE001, a Novel Therapeutic Candidate for the Treatment of Pompe Disease
From Shionogi USA
Via Business Wire
ESCMID Global 2024: Shionogi presents real-world data demonstrating efficacy of Fetcroja® / Fetroja® (cefiderocol) in critically ill patients with certain difficult-to-treat bacterial infections
From Shionogi USA
Via Business Wire
Shionogi Announces New Phase 3 Data Showing Early Resolution of Many Common COVID-19 Symptoms in JAMA Network Open
From Shionogi USA
Via Business Wire
Shionogi Strengthens Regulatory Leadership with the Appointment of Dr. Ramón Polo as Senior Vice President, Head of Regulatory Affairs
From Shionogi USA
Via Business Wire
Shionogi Presents New Ensitrelvir COVID-19 Data Supporting Effectiveness in Real-World and Clinical Settings at IDWeek 2023
From Shionogi USA
Via Business Wire
IDWeek 2023: Shionogi Presents New Real-World Evidence Demonstrating Effectiveness of Earlier Treatment with Fetroja® (cefiderocol) in Appropriate Patients
From Shionogi USA
Via Business Wire
Zatolmilast, an Investigational Treatment for Fragile X Syndrome, Receives Rare Pediatric Disease Designation from the U.S. FDA
From Shionogi USA
Via Business Wire
Shionogi Presents New Ensitrelvir Clinical and Real-World Data Reinforcing Potential Across COVID-19 Populations at ESWI 2023
From Shionogi USA
Via Business Wire
Critical agreement paves way for new model to accelerate access to important antibiotics for serious bacterial infections
From Shionogi USA
Via Business Wire
IDWeek 2023: Shionogi and Qpex Biopharma, Inc. Continue Longstanding Commitment to Addressing Unmet Needs in Infectious Disease
From Shionogi USA
Via Business Wire
Shionogi Further Extends Infectious Disease Innovation Platform with Planned Acquisition of Qpex Biopharma, Inc.
From Shionogi USA
Via Business Wire
Shionogi Enrolls the First Participant in Japan in its Global Phase 3 Trial of Ensitrelvir for the Prevention of Symptomatic SARS-CoV-2 Infection
From Shionogi USA
Via Business Wire
ECCMID 2023: Shionogi Announces Real-World Evidence Demonstrating the Efficacy of Fetcroja® / Fetroja® (cefiderocol) Against Some of the Most Difficult-to-Treat Gram-Negative Bacterial Pathogens
From Shionogi USA
Via Business Wire
Shionogi Receives U.S. FDA Fast Track Designation for Ensitrelvir Fumaric Acid, an Investigational Oral Antiviral for COVID-19
From Shionogi USA
Via Business Wire
Shionogi Presents Pivotal Ensitrelvir Fumaric Acid Phase 3 Data and Exploratory Long COVID Data at CROI
From Shionogi USA
Via Business Wire
Shionogi Presents Real-World Evidence Showing Strong Efficacy with Fetroja® (cefiderocol) Against Treatment Resistant Bacterial Infections at IDWeek 2022
From Shionogi USA
Via Business Wire
Shionogi, GARDP and CHAI Announce Landmark License and Collaboration Agreements to Treat Bacterial Infections by Expanding Access to Cefiderocol in 135 Countries
From Shionogi USA
Via Business Wire
Shionogi Announces Strategic Re-Organization of U.S. Executive Leadership
From Shionogi USA
Via Business Wire
New Data for Shionogi’s COVID-19 Once-Daily Oral Antiviral S-217622 Show Rapid Virus Clearance
From Shionogi USA
Via Business Wire
Shionogi Presents the Results of COVID-19 Therapeutic Agent at ISIRV-WHO Virtual Conference
From Shionogi USA
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.